Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D O Jones

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The Journal of Investigative Dermatology|March 1, 1997
A new keratin 2e mutation in ichthyosis bullosa of SiemensD O Jones, C Watts, C Mills, et al.
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical and Translational Science|November 10, 2025
Predicting the Pharmacokinetics of T-Cell Engagers as a Function of Target-Mediated Drug DispositionMark Penney, Alberto Ippolito, Elisa Fevola, et al.
Nature Genetics|July 1, 1995
Mutation of a type II keratin gene (K6a) in pachyonychia congenitaP E Bowden, J L Haley, A Kansky, et al.
The Journal of Investigative Dermatology|February 11, 1998
Characterization and chromosomal localization of human hair-specific keratin genes and comparative expression during the hair growth cycleP E Bowden, S D Hainey, G Parker, et al.
Trends in Pharmacological Sciences|May 4, 2020
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two DecadesMichael Davies, Rhys D O Jones, Ken Grime, et al.
Communications Biology|November 6, 2025
A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomesTashinga E Bapiro, Scott Martin, Thomas S Blacker, et al.
The AAPS Journal|June 28, 2023
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse ModelsMichael J White, Letitia Cheatham, Shenghua Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
British Journal of Pharmacology|October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activityRhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The Journal of Investigative Dermatology|March 1, 1997
A new keratin 2e mutation in ichthyosis bullosa of SiemensD O Jones, C Watts, C Mills, et al.
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical and Translational Science|November 10, 2025
Predicting the Pharmacokinetics of T-Cell Engagers as a Function of Target-Mediated Drug DispositionMark Penney, Alberto Ippolito, Elisa Fevola, et al.
Nature Genetics|July 1, 1995
Mutation of a type II keratin gene (K6a) in pachyonychia congenitaP E Bowden, J L Haley, A Kansky, et al.
The Journal of Investigative Dermatology|February 11, 1998
Characterization and chromosomal localization of human hair-specific keratin genes and comparative expression during the hair growth cycleP E Bowden, S D Hainey, G Parker, et al.
Trends in Pharmacological Sciences|May 4, 2020
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two DecadesMichael Davies, Rhys D O Jones, Ken Grime, et al.
Communications Biology|November 6, 2025
A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomesTashinga E Bapiro, Scott Martin, Thomas S Blacker, et al.
The AAPS Journal|June 28, 2023
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse ModelsMichael J White, Letitia Cheatham, Shenghua Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
British Journal of Pharmacology|October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activityRhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Pageof 3